Erytech Pharma S.A. (ERYP)
| Market Cap | 253.57M |
| Revenue (ttm) | 5.94M |
| Net Income (ttm) | -70.40M |
| Shares Out | 17.94M |
| EPS (ttm) | -2.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $12.28 |
| Previous Close | $12.01 |
| Change ($) | 0.27 |
| Change (%) | 2.23% |
| Day's Open | 12.86 |
| Day's Range | 11.21 - 12.93 |
| Day's Volume | 7,560 |
| 52-Week Range | 3.85 - 12.93 |
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating ...
ERYTECH to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by enc...
LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by enc...
LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
W ebcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET
Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET
LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferie...
ERYTECH Pharma's (ERYP) CEO Gil Beyen on Q3 2020 Results - Earnings Call Transcript
Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET
LYON, France and CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by en...
Article 223-16 of general regulation of French Autorité des Marchés Financiers
LYON, France and CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by enc...
LYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulati...
LYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by enc...
ERYTECH is progressing a phase 3 trial in pancreatic cancer. The drug, reformulated L-asparaginase, has known anti-cancer properties but its safety profile needs to be good.
Article 223-16 of general regulation of French Autorité des Marchés Financiers
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q2 2020 Results - Earnings Call Transcript
LYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsu...
LYON, France, Sept. 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsula...
LYON, France and CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...
LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
Erytech is a company with a promising novel method targeting the large cancer market with unmet needs.
LYON, France, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
LYON, France, July 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
LYON, France and CAMBRIDGE, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Frid...
Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached Agreement with Alpha B...
LYON, France, June 09, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
LYON, France and CAMBRIDGE, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by ...
Erytech Pharma SA Sponsored ADR (ERYP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2020 Results - Earnings Call Transcript
LYON, France, May 07, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
Conference call and webcast on Thursday, May 7 at 2:30 pm CET/8:30 am ET
LYON, France and CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by en...
LYON, France and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...
LYON, France and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based ca...
LYON, France, April 20, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, to...
LYON, France, April 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
ERYTECH Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F
LYON, France and CAMBRIDGE, Mass., March 19, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by...
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2019 Results - Earnings Call Transcript
LYON, France and CAMBRIDGE, Mass. , March 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies b...
Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers
Second European source of donor red blood cells secured in preparation for expanded production of red blood cell-based therapeutics
Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers
As of late, it has definitely been a great time to be an investor ERYTECH Pharma.
Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers
Article 223-16 of general regulation of French Autorité des Marchés Financiers Article 223-16 of general regulation of French Autorité des Marchés Financiers
First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors
About ERYP
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ER... [Read more...]
| Industry Biotechnology | Founded 2004 |
| CEO Gil Beyen | Employees 217 |
| Stock Exchange NASDAQ | Ticker Symbol ERYP |
Financial Performance
In 2019, Erytech Pharma's revenue was 5.28 million, an increase of 18.80% compared to the previous year's 4.45 million. Losses were -62.66 million, 63.9% more than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for Erytech Pharma stock is "Strong Buy." The 12-month stock price forecast is 17.89, which is an increase of 45.68% from the latest price.